Croop R, Goadsby PJ, Stock DA et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet 394(10200):737–745

Article  CAS  Google Scholar 

Migraine research foundation. Migraine research 2019; https://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed July 8, 2020.

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1211–1259

Article  Google Scholar 

Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19(1):17

Article  PubMed  PubMed Central  Google Scholar 

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343–349

Article  PubMed  CAS  Google Scholar 

Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache The Journal of Head and Face Pain 41(7):646–657

Article  CAS  Google Scholar 

Landy SH, Runken MC, Bell CF, Higbie RL, Haskins LS (2011) Assessing the impact of migraine onset on work productivity. J Occup Environ Med 53(1):74–81

Article  PubMed  Google Scholar 

Ailani J, Burch RC, Robbins MS, Society BoDotAH. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain. 2021;61(7):1021–39.

Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews. 2012;(2):CD008615.

Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC (2017) Framingham‐based cardiovascular risk estimates among people with episodic migraine in the US population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache: The Journal of Head and Face Pain 57(10):1507–1521

Article  Google Scholar 

Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB (2017) Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache The Journal of Head and Face Pain 57(1):31–44

Article  Google Scholar 

Lipton RB, Buse DC, Serrano D, Holland S, Reed ML (2013) Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache: The Journal of Head and Face Pain 53(8):1300–1311

Article  Google Scholar 

Katić BJ, Rajagopalan S, Ho TW, Chen Y-T, Hu XH (2011) Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia 31(4):488–500

Article  PubMed  Google Scholar 

Ng-Mak DS, Chen YT, Ho TW, Stanford B, Roset M (2012) Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases. Cephalalgia 32(12):875–887

Article  PubMed  Google Scholar 

Chen TB, Chen YT, Fuh JL, Tang CH, Wang SJ. Treatment adherence among new triptan users: a 2-year cohort study in Taiwan. J Headache Pain. 2014;15(1):48.

Messali A, Owens G, Bloudek L, Kori S, Cole A, Chia J (2014) Health care resource utilization following initiation of a triptan: A retrospective claims analysis. J Manag Care Pharm 20(4):368–375

Google Scholar 

Feigin VL, Abajobir AA, Abate KH et al (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology 16(11):877–897

Article  Google Scholar 

Puledda F, Sacco S, Diener HC et al (2024) International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44(8):3331024241252666

Article  PubMed  Google Scholar 

Green MW (2021) Medication overuse headache. Curr Opin Neurol 34(3):378–383

Article  PubMed  CAS  Google Scholar 

Allergan Pharmaceuticals. UBRELVY (ubrogepant) [package insert]. U.S. Food and Drug Administration website. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf. Accessed 27 Sept 2024.

Biohaven Pharmaceuticals, Inc. NURTEC ODT (rimegepant) [package insert]. U.S. Food and Drug Administration website. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf. Accessed 27 Sept 2024.

Hubig LT, Smith T, Chua GN et al (2022) A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache 62(9):1187–1197

Article  PubMed  PubMed Central  Google Scholar 

Lipton RB, Stewart WF (1999) Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache: The Journal of Head and Face Pain 39:S20–S26

Article  Google Scholar 

Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M (2003) Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 17(9):653–667

Article  PubMed  CAS  Google Scholar 

Smith T, Tickler G, Skrobanski H et al (2023) Patient experiences and preferences for non-oral acute migraine treatments: A qualitative interview study, American Headache Society 65th Annual Scientific Meeting June 15–18, 2023 Austin, Texas. Headache: The Journal of Head and Face Pain 63(S1):1–205

Article  Google Scholar 

Martin V, Hoekman J, Aurora SK, Shrewsbury SB. Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space. J Clin Med. 2021;10(11):2468.

Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD (2004) Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs 18(10):671–685

Article  PubMed  CAS  Google Scholar 

Silberstein SD, Shrewsbury SB, Hoekman J (2020) Dihydroergotamine (DHE) - Then and Now: A Narrative Review. Headache 60(1):40–57

Article  PubMed  Google Scholar 

Tfelt-Hansen P (2001) Ergotamine, dihydroergotamine: current uses and problems. Curr Med Res Opin 17(Suppl 1):s30-34

Article  PubMed  Google Scholar 

Tfelt-Hansen PC, Diener HC (2014) Use of dihydroergotamine (DHE) should be restricted to no more than twice a week. Headache 54(9):1523–1525

Article  PubMed  Google Scholar 

Tfelt-Hansen P, Saxena P. Ergot alkaloids in the acute treatment of migraine. The headaches, second edition. 2000. p. 467–76.

ZAVZPRET™ (zavegepant) nasal spray. 2023; https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf. Accessed 13th April 2023.

Lipton RB, Croop R, Stock DA et al (2023) Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. The Lancet Neurology 22(3):209–217

Article  PubMed  CAS  Google Scholar 

Joshi S, Smith T, Pavlovic J, et al. Efficacy of Zavegepant Nasal Spray for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials. 2023; https://index.mirasmart.com/aan2023/index.php. Accessed 2023–08–21.

Joshi S, Smith T, Pavlovic J et al (2023) Efficacy of Zavegepant Nasal Spray for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials, American Headache Society 65th Annual Scientific Meeting June 15–18, 2023 Austin, Texas. Headache: The Journal of Head and Face Pain 63(S1):1–205

Google Scholar 

Diener HC, Tassorelli C, Dodick DW et al (2019) Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia 39(6):687–710

Article  PubMed  PubMed Central  Google Scholar 

SAS Institute Inc. "The MI Procedure" in SAS/STAT® 15.3 User’s Guide. Cary: SAS Institute Inc; 2023.

Cohen J. Statistical Power Analysis for the Behavioral Sciences. Cambridge: Academic Press; 2013. https://doi.org/10.4324/9780203771587.

Mathew NT, Kailasam J, Meadors L (2004) Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 44(7):669–673

Article  PubMed  Google Scholar 

Lipton RB, Stewart WF, Stone AM, Láinez MJ, Sawyer JP (2000) Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 284(20):2599–2605

Article  PubMed  CAS  Google Scholar 

Cady RK, Lipton RB, Hall C, Stewart WF, O’Quinn S, Gutterman D (2000) Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 40(10):792–797

Article  PubMed  CAS  Google Scholar 

Pascual J, García-Moncó C, Roig C, Yusta Izquierdo A, López-Gil A (2005) Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference. Headache 45(9):1140–1150

Article  PubMed  Google Scholar 

Christoph-Diener H, Ferrari M, Mansbach H (2004) Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology 63(3):520–524

Article  PubMed  CAS  Google Scholar 

Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B (2008) Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia 28(1):35–40